Key result
Five patients with affective disorders developed tardive dyskinesia after treatment with second-generation atypical antipsychotics, demonstrating that the risk of this side effect remains present with newer agents.
Why the study?
Do atypical antipsychotics increase the risk of tardive dyskinesia in psychiatric patients?
Case Report (n=5)
No
Do atypical antipsychotics increase the risk of tardive dyskinesia in psychiatric patients?
Atypical antipsychotics carry a risk of inducing tardive dyskinesia, necessitating continued diligence in monitoring and informed consent.
May warrant continued TD monitoring with atypical antipsychotics; leaves open comparative risk quantification in affective disorders.
Tardive dyskinesia (TD) is a disfiguring side-effect of antipsychotic medications that is potentially irreversible in affected patients. Newer atypical antipsychotics are felt by many to have a lower risk of TD. As a result, many clinicians may have developed a false sense of security when prescribing these medications. We report five cases of patients taking atypical antipsychotics who developed TD, review the risk of TD, its potential etiologic mechanisms, and treatment options available. The goal of this paper is to alert the reader to continue to be diligent in obtaining informed consent and monitoring for the onset of TD in patients taking atypical antipsychotics.
No takes yet. Share an insight, caveat, or question.
MacMaster et al. (2014) conducted a case report in Tardive dyskinesia (n=5). Atypical antipsychotics was evaluated on Development of tardive dyskinesia. Five patients with affective disorders developed tardive dyskinesia after treatment with second-generation atypical antipsychotics, demonstrating that the risk of this side effect remains present with newer agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: